Attovia Therapeutics Inc.
ATTO | NASDAQ
$20.34
-$0.96 (-4.51%)
Sep 22, 2026, 12:16 PM ET · Market open
TTM Period Ending | Q2 2026 Jun 29, 2026 | Q1 2026 Mar 30, 2026 | Q1 2025 Mar 30, 2025 |
|---|---|---|---|
Revenue | 450K | n/a | n/a |
Cost of Revenue | 488K | 242K | 143K |
Gross Profit | -38K | -242K | -143K |
Operating Income | -41.76M | -19.96M | -16.1M |
Interest Income | 2.47M | 1.33M | 1.13M |
Pretax Income | -39.34M | -18.66M | -15.15M |
Net Income | -39.34M | -18.66M | -15.15M |
Selling & General & Admin | 6.03M | 2.97M | 4.11M |
Research & Development | 35.69M | 16.75M | 11.86M |
Other Expenses | n/a | n/a | n/a |
Operating Expenses | 41.72M | 19.71M | 15.96M |
Interest Expense | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a |
Cost & Expenses | 42.21M | 19.96M | 16.1M |
Income Tax Expense | n/a | n/a | n/a |
Shares Outstanding (Basic) | 45.65M | 38.53M | 38.53M |
Shares Outstanding (Diluted) | 45.65M | 38.53M | 38.53M |
EPS (Basic) | -0.93 | -0.48 | -0.40 |
EPS (Diluted) | -0.93 | -0.48 | -0.40 |
EBITDA | -41.27M | -19.71M | -15.96M |
EBIT | -41.76M | -19.96M | -16.1M |
Depreciation & Amortization | 488K | 242K | 143K |
Add to Watchlist
Select watchlists to add or remove ATTO